Carbone C - Search Results

1

Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.

Carbone C, Tamburrino A, Piro G, Boschi F, Cataldo I, Zanotto M, Mina MM, Zanini S, Sbarbati A, Scarpa A, Tortora G, Melisi D. Carbone C, et al. Anticancer Drugs. 2016 Jan;27(1):29-40. doi: 10.1097/CAD.0000000000000301. Anticancer Drugs. 2016. PMID: 26473526

2

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A. Bruzzese F, et al. Among authors: carbone c. J Cell Physiol. 2011 Sep;226(9):2378-90. doi: 10.1002/jcp.22574. J Cell Physiol. 2011. PMID: 21660961

3

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D. Carbone C, et al. Clin Cancer Res. 2011 Sep 1;17(17):5822-32. doi: 10.1158/1078-0432.CCR-11-1185. Epub 2011 Jul 7. Clin Cancer Res. 2011. PMID: 21737511 Free PMC article.

4

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ. Melisi D, et al. Among authors: carbone c. J Natl Cancer Inst. 2011 Aug 3;103(15):1190-204. doi: 10.1093/jnci/djr243. Epub 2011 Jul 8. J Natl Cancer Inst. 2011. PMID: 21743023 Free PMC article.

5

NF-κB as a target for pancreatic cancer therapy.

Carbone C, Melisi D. Carbone C, et al. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S1-10. doi: 10.1517/14728222.2011.645806. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443181 Review.

6

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.

Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Tamburrino A, et al. Among authors: carbone c. Front Pharmacol. 2013 Apr 30;4:56. doi: 10.3389/fphar.2013.00056. eCollection 2013. Front Pharmacol. 2013. PMID: 23641216 Free PMC article.

7

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Milone MR, et al. Among authors: carbone c. Cell Death Dis. 2013 May 23;4(5):e641. doi: 10.1038/cddis.2013.165. Cell Death Dis. 2013. PMID: 23703386 Free PMC article.

8

Rationale and clinical use of multitargeting anticancer agents.

Melisi D, Piro G, Tamburrino A, Carbone C, Tortora G. Melisi D, et al. Among authors: carbone c. Curr Opin Pharmacol. 2013 Aug;13(4):536-42. doi: 10.1016/j.coph.2013.06.012. Epub 2013 Jul 13. Curr Opin Pharmacol. 2013. PMID: 23856428 Review.

9

An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis.

Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanotto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, Melisi D. Carbone C, et al. Oncotarget. 2015 May 30;6(15):13822-34. doi: 10.18632/oncotarget.2635. Oncotarget. 2015. PMID: 25360865 Free PMC article.

10

Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.

Simionato F, Frizziero M, Carbone C, Tortora G, Melisi D. Simionato F, et al. Among authors: carbone c. Curr Drug Metab. 2015;16(7):585-96. doi: 10.2174/1389200216666150812142059. Curr Drug Metab. 2015. PMID: 26264346 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

503 results

Search Page